Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Favipiravir [259793-96-9]
Katalog-Nummer T6833-5mg
Size : 5mg
Marke : TargetMol
Contact local distributor :
Telefonnummer : +1 850 650 7790
Favipiravir
Catalog No. T6833 CAS 259793-96-9
Synonyms: T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide
Favipiravir (T-705) (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Favipiravir, CAS 259793-96-9
| Description | Favipiravir (T-705) (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections. |
| Targets&IC50 | RdRP:341 nM. |
| In vitro | Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2] |
| In vivo | In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3] |
| Cell Research | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
| Synonyms | T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide |
| Molecular Weight | 157.1 |
| Formula | C5H4FN3O2 |
| CAS No. | 259793-96-9 |
Storage
Solubility Information
Ethanol: 12 mg/mL(76.4 mM)
H2O: 5 mg/mL (31.82 mM)
DMSO: 29 mg/mL (184.6 mM)
References and Literature
1. Furuta Y, et al. Antimicrob Agents Chemother. 2002, 46(4), 977-981. 2. Baranovich T, et al. J Virol. 2013, 87(7), 3741-3751. 3. Madelain V, et al. Antiviral Res. 2015, 123, 70-77. 4. WEI X U, Shuai X, Jing P, et al. The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses[J]. Frontiers in Microbiology. 2018 Nov 6;9:2643. 5. Qiu M, Li Z, Chen Y, et al. Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. Frontiers in Microbiology. 2020, 11: 504.
Citations
1. Nicholson M W, Huang C Y, Wang J Y, et al. Cardio-and Neurotoxicity of Selected Anti-COVID-19 Drugs. Pharmaceuticals. 2022, 15(6): 765 2. Qiu M, Li Z, Chen Y, et al. Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. Frontiers in Microbiology. 2020, 11: 504 3. WEI X U, Shuai X, Jing P, et al. The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses. Frontiers in Microbiology. 2018 Nov 6;9:2643 4. Zhang J, He M, Xie Q, et al.Predicting In Vitro and In Vivo Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity.ACS Omega.2022 5. Westover J B, Jung K H, Alkan C, et al.Modeling Heartland virus disease in mice and therapeutic intervention with 4′-fluorouridine.Journal of Virology.2024: e00132-24.